COMPANY

Dynavax Technologies Corporation

HQ: Emeryville, CA source · dynavax.com ↗ · West Coast

FDA-approved therapeutic company Clinical Phase 2

For the diagnostic market, we have used our vaccine production technologies to manufacture and supply recombinant antigens. Dynavax wholly owns, manufactures and holds worldwide commercial rights to HEPLISAV-B. From company website Source · Oct 12, 2026

Keywords: diagnostic vaccine Vaccine-Preventable Diseases Hepatitis B rheumatoid arthritis skin inflammation lupus Shingles Herpes Zoster Chronic Kidney Disease Rhinitis, Allergic, Seasonal autoimmune diseases influenza Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis Pneumonic Plague Plague End Stage Renal Disease on Hemodialysis (Diagnosis) Pregnant Metastatic Melanoma Head Neck Cancer B-cell Lymphoma Advanced Non Small Cell Lung Cancer Chronic Hepatitis B Chronic Hepatitis C Colorectal Neoplasms End Stage Renal Disease hepatic fibrosis cirrhosis respiratory allergy Z-1018 SD-101 Engerix-B HEPLISAV-B® HEPLISAV-B DV281 DV281 (RP2D) DV-601 1018 ISS immunostimulatory oligonucleotide

Location: Emeryville, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

25Trials (company is sponsor)37NIH grants

Timeline

Sep 11, 2025 Trial start Phase 2: Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age source ↗
Jun 17, 2024 Trial start Phase 1/Phase 2: Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over source ↗
Aug 9, 2022 Trial start Phase 2: Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age source ↗
Jan 10, 2022 Trial start Phase 1: Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers source ↗
Feb 21, 2021 Trial start —: DV2-HBV-27: Observational Pregnancy Registry source ↗
Apr 22, 2019 Trial start Phase 1: HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis source ↗
Sep 20, 2017 Trial start 1: Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC source ↗
2015-09 Trial start Phase 1/Phase 2: A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma source ↗
2014-10 Trial start Phase 1/Phase 2: Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma source ↗
2014-04 Trial start Phase 3: Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine source ↗
2013-11 Trial start Phase 1: A Study of the Immune Response to Heplisav in Healthy Older Adults source ↗
2010-12 Trial start Phase 3: Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis source ↗
2010-12 Trial start —: Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease source ↗
2010-02 Trial start Phase 3: Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine source ↗
2009-09 Trial start Phase 3: Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients source ↗
2009-09 Trial start Phase 1: A Study to Assess DV-601 in Subjects With Chronic Hepatitis B source ↗
2008-10 Trial start Phase 1: Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection source ↗
2008-01 Trial start Phase 1: Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males source ↗
2007-09 Trial start Phase 2: An Evaluation of the Efficacy and Safety of TOLAMBA™ for Ragweed-Allergic Rhinitis in an Environmental Exposure Chamber source ↗
2007-07 Trial start Phase 2: A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease source ↗
2007-06 Trial start Phase 2: Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine source ↗
2006-12 Trial start Phase 3: Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine source ↗
2006-11 Trial start Phase 1: A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer source ↗
2006-04 Trial start Phase 2: Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults source ↗
2006-01 Trial start Phase 1: Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients source ↗

Upcoming milestones

Jan 29, 2027 (ESTIMATED) · Phase 2 · Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age · NCT07207408
2027-11 (ESTIMATED) · Phase 1/Phase 2 · Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over · NCT06569823

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 25

Record	Title	Phase	Status	Start	Primary completion
NCT07207408	Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age	Phase 2	Active, not recruiting	Sep 11, 2025	Jan 29, 2027 (estimated)
NCT06569823	Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over	Phase 1/Phase 2	Active, not recruiting	Jun 17, 2024	2027-11 (estimated)
NCT05506969	Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age	Phase 2	Completed	Aug 9, 2022	Oct 3, 2023 (actual)
NCT03934736	HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis	Phase 1	Completed	Apr 22, 2019	Oct 23, 2020 (actual)
NCT03664648	DV2-HBV-27: Observational Pregnancy Registry	Not listed	Unknown status (ClinicalTrials.gov)	Feb 21, 2021	2024-09 (estimated)
NCT05245838	Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers	Phase 1	Completed	Jan 10, 2022	Oct 20, 2022 (actual)
NCT02521870	A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Phase 1/Phase 2	Terminated	2015-09	2020-04 (actual)
NCT00985426	Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients	Phase 3	Completed	2009-09	2012-01 (actual)
NCT02266147	Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma	Phase 1/Phase 2	Terminated	2014-10	2017-04 (actual)
NCT03326752	Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC	1	Completed	Sep 20, 2017	Sep 19, 2019 (actual)
NCT00511095	Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine	Phase 2	Completed	2007-06	2007-10 (actual)
NCT01023230	A Study to Assess DV-601 in Subjects With Chronic Hepatitis B	Phase 1	Completed	2009-09	2011-05 (actual)
NCT00537355	An Evaluation of the Efficacy and Safety of TOLAMBA™ for Ragweed-Allergic Rhinitis in an Environmental Exposure Chamber	Phase 2	Completed	2007-09	2008-03 (actual)
NCT00823862	Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection	Phase 1	Completed	2008-10	2009-12 (actual)
NCT00403052	A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer	Phase 1	Terminated	2006-11	2007-12 (actual)
NCT00599001	Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males	Phase 1	Completed	2008-01	2008-03 (actual)
NCT00387738	Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults	Phase 2	Terminated	2006-04	2007-05 (actual)
NCT00498212	A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease	Phase 2	Terminated	2007-07	2008-08 (actual)
NCT02117934	Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine	Phase 3	Completed	2014-04	2015-10 (actual)
NCT01999699	A Study of the Immune Response to Heplisav in Healthy Older Adults	Phase 1	Completed	2013-11	2015-02 (actual)
NCT01005407	Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine	Phase 3	Completed	2010-02	2011-01 (actual)
NCT00435812	Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine	Phase 3	Completed	2006-12	2008-02 (actual)
NCT01195246	Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis	Phase 3	Completed	2010-12	2012-02 (actual)
NCT01282762	Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease	Not listed	Completed	2010-12	2013-08 (actual)
NCT00426712	Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients	Phase 1	Completed	2006-01	2008-03 (actual)

NIH awards 37

Annual award amounts. Total $35.2M.

Jan 27, 2017 NIH award 5R44AI100376-04 FY2017: $422,785 awarded for that fiscal year; activity R44 (SBIR); PI CANDIA, ALBERT F; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. Developing small molecule inhib source ↗
Feb 11, 2016 NIH award 2R44AI100376-03 FY2016: $589,482 awarded for that fiscal year; activity R44 (SBIR); PI CANDIA, ALBERT F; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. Developing small molecule inhib source ↗
Apr 29, 2015 NIH award 5R21OD018317-02 FY2015: $198,117 awarded for that fiscal year; activity R21 (OTHER_NIH); PI GUIDUCCI, CRISTIANA; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. Generation of a Transge source ↗
Aug 1, 2014 NIH award 1R21OD018317-01 FY2014: $227,161 awarded for that fiscal year; activity R21 (OTHER_NIH); PI GUIDUCCI, CRISTIANA; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. Generation of a Transge source ↗
Sep 20, 2013 NIH award 1R41DK101221-01 FY2013: $223,390 awarded for that fiscal year; activity R41 (STTR); PI CANDIA, ALBERT F; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. The Development of TLR Antagoni source ↗
Jun 7, 2013 NIH award 5R43AI100376-02 FY2013: $105,088 awarded for that fiscal year; activity R43 (SBIR); PI COFFMAN, ROBERT L; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. Screening for Inhibitors of TL source ↗
May 23, 2013 NIH award 5R43AI096641-02 FY2013: $299,508 awarded for that fiscal year; activity R43 (SBIR); PI GUIDUCCI, CRISTIANA; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. Development of TLR8 inhibito source ↗
Jun 22, 2012 NIH award 5R43AI092929-02 FY2012: $292,359 awarded for that fiscal year; activity R43 (SBIR); PI GUIDUCCI, CRISTIANA; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. Inhibitors of PI3K-delta for source ↗
May 29, 2012 NIH award 1R43AI100376-01A1 FY2012: $299,830 awarded for that fiscal year; activity R43 (SBIR); PI COFFMAN, ROBERT L; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. Screening for Inhibitors of source ↗
May 22, 2012 NIH award 1R43AI096641-01A1 FY2012: $299,508 awarded for that fiscal year; activity R43 (SBIR); PI GUIDUCCI, CRISTIANA; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. Development of TLR8 inhibi source ↗
2012 NIH contract (government contract; not a grant and not an investment round) 272200800038C-5-0-1 FY2012: $2,248,871 awarded for that fiscal year; activity N01 (OTHER_NIH); PI LANGE, LAURA; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. Ad source ↗
Jul 18, 2011 NIH award 1R43AI092929-01 FY2011: $297,225 awarded for that fiscal year; activity R43 (SBIR); PI GUIDUCCI, CRISTIANA; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. Inhibitors of PI3K-delta for source ↗
Jul 14, 2011 NIH award 5R43CA154078-02 FY2011: $297,200 awarded for that fiscal year; activity R43 (SBIR); PI HILLEBRAND, ANNETTE; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. Development of an L2-based H source ↗
2011 NIH contract (government contract; not a grant and not an investment round) 272200800038C-3-0-1 FY2011: $9,711,242 awarded for that fiscal year; activity N01 (OTHER_NIH); PI SEAMON, BRADFORD; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA source ↗
Jul 7, 2010 NIH award 1R43CA154078-01 FY2010: $298,625 awarded for that fiscal year; activity R43 (SBIR); PI HILLEBRAND, ANNETTE; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. Development of an L2-based H source ↗
Mar 18, 2010 NIH award 5R43AI082839-02 FY2010: $360,909 awarded for that fiscal year; activity R43 (SBIR); PI BARRAT, FRANCK; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. Inhibitors of Toll-like receptors source ↗
Jun 26, 2009 NIH award 5R44AI066483-03 FY2009: $932,510 awarded for that fiscal year; activity R44 (SBIR); PI COFFMAN, ROBERT L; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. Development of an inhibitory o source ↗
Mar 26, 2009 NIH award 1R43AI082839-01 FY2009: $359,430 awarded for that fiscal year; activity R43 (SBIR); PI BARRAT, FRANCK; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. Inhibitors of Toll-like receptors source ↗
2009 NIH contract (government contract; not a grant and not an investment round) 272200800038C-2-0-1 FY2009: $1,673,631 awarded for that fiscal year; activity N01 (OTHER_NIH); PI VAN NEST, GARY A; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA source ↗
Aug 6, 2008 NIH award 5U01AI074578-02 FY2008: $1,616,687 awarded for that fiscal year; activity U01 (OTHER_NIH); PI VAN NEST, GARY A; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. Production of an NP-ISS source ↗
Jul 7, 2008 NIH award 2R44AI066483-02 FY2008: $878,519 awarded for that fiscal year; activity R44 (SBIR); PI COFFMAN, ROBERT L; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. Development of an inhibitory o source ↗
2008 NIH contract (government contract; not a grant and not an investment round) 272200800038C-1-0-1 FY2008: $3,227,796 awarded for that fiscal year; activity N01 (OTHER_NIH); PI n/a; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. Adjuvant De source ↗
Aug 6, 2007 NIH award 1U01AI074578-01 FY2007: $1,600,000 awarded for that fiscal year; activity U01 (OTHER_NIH); PI VAN NEST, GARY A; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. Production of an NP-ISS source ↗
Jul 20, 2006 NIH award 1R43AI066483-01A1 FY2006: $207,278 awarded for that fiscal year; activity R43 (SBIR); PI COFFMAN, ROBERT L; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. Development of an Inhibitory source ↗
Jul 17, 2006 NIH award 5U01AI056447-04 FY2006: $1,767,169 awarded for that fiscal year; activity U01 (OTHER_NIH); PI VAN NEST, GARY A; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. ISS-linked NP vaccine to source ↗
Jan 25, 2006 NIH award 5U01AI056559-04 FY2006: $2,098,735 awarded for that fiscal year; activity U01 (OTHER_NIH); PI VAN NEST, GARY A; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. Advanced anthrax vaccine source ↗
Mar 16, 2005 NIH award 5U01AI056435-03 FY2005: $202,329 awarded for that fiscal year; activity U01 (OTHER_NIH); PI COFFMAN, ROBERT L; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. Immunostimulatory DNA Pri source ↗
Feb 14, 2005 NIH award 5U01AI056447-03 FY2005: $534,847 awarded for that fiscal year; activity U01 (OTHER_NIH); PI VAN NEST, GARY A; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. ISS-linked NP vaccine to c source ↗
Feb 7, 2005 NIH award 5U01AI056559-03 FY2005: $816,464 awarded for that fiscal year; activity U01 (OTHER_NIH); PI VAN NEST, GARY A; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. Advanced anthrax vaccine m source ↗
May 24, 2004 NIH award 5U01AI056435-02 FY2004: $759,577 awarded for that fiscal year; activity U01 (OTHER_NIH); PI COFFMAN, ROBERT L; recipient as written: DYNAVAX TECHNOLOGIES CORPORATION, BERKELEY, CA. Immunostimulatory DNA Pri source ↗

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of Bain Capital Life Sciences (captured Oct 12, 2026). portfolio page ↗